Agent | Trial number | Disease status | Phase | N | Results (N; duration) |
---|---|---|---|---|---|
Ipilimumab | NCT01611558 | Recurrent | II | 40 | 10% BRR (4; N/A) |
BMS-936559 (anti-PD-L1) | NCT00729664 | Advanced stage | I | 17 | 6% PR (1; 1.3+ months) 15% SD (3; 6+ months) |
Nivolumab | UMIN0005714 | Pt-resistant Relapsed | II | 2 | 10% CR (2; 11+ months) 5% PR (1; 11+ months) 30% SD (6; 1 for 11+ months) |
Pembrolizumab | NCT02054806 | Advanced stage PD-L1+ | Ib | 26 | 4% CR (1; 6+ months) 8% PR (2; 6+ months) 23% SD (8; 2 for 6+ months) |
Avelumab | NCT01772004 | Pt-resistant Recurrent | Ib | 124 | 10% PR (12; 4 for 6+ months) 44% SD (55; N/A) |
Durvalumab (+ olaparib) | NCT02484404 | Recurrent | I/II | 10 | PR (1; 11+ months) SD (7; 4+ months) |